TEMPUS | ONCOLOGY

The Comprehensive Solution with Tempus

We offer a broad range of molecular testing services to help physicians make informed treatment decisions.

Tests and services described below are those available in the EU and UK.

TESTS FOR INFORMING TREATMENT SELECTION

xT DNA

Solid Tumor + Normal Match

648 gene panel by DNA seq with incidental germline findings

Tumor + normal match

Immunotherapy Metrics
Microsatellite Instability (MSI) Status
Tumor Mutational Burden(TMB)

TISSUE (from pathology department)
+
BLOOD (2) 8.5mL Streck tubes filled with peripheral blood*

+

xR (RNA)

Solid Tumor

Whole transcriptome RNA seq with validated fusion detection.

Altered splicing for MET, Exon 14, and EGFRvIII. *May be ordered as a standalone or in combination with xT (DNA) seq.*

TISSUE (from pathology department)

---

xF/xF+ Liquid Biopsy

Blood (liquid biopsy, cfDNA)

105/523 gene panel by DNA seq.

Immunotherapy Markers
MSI-High Status;
Blood-based Tumor Mutational Burden (bTMB) – available only in the xF+ report.

BLOOD (2) 8.5mL Streck tubes filled with peripheral blood

---

xE Whole Exome

Solid Tumor + Normal Match

Whole exome 19,000+ gene panel by DNA seq with potential germline findings

Immunotherapy Markers
Tumor Mutational Burden (TMB)

TISSUE (from pathology department)
+
BLOOD (2) 8.5mL Streck tubes filled with peripheral blood*

ALGORITHMIC TESTS—Available as add-on test to xT Solid Tumor/Normal Match DNA seq and xR RNA seq. No additional tissue required.

HRD **Homologous Recombination Deficiency**	**DNA seq:** Genome-wide loss of heterozygosity threshold for ovarian and breast cancers[§]	**RNA seq:** HRD score (all other cancers)[¶]
TO **Tumor Origin**[¶]	**RNA expression data:** Probability prediction of the patient's most likely cancer type(s) from 68 possible diagnoses.	
DPYD[§]	Identifies patients at elevated risk for toxicity to 5-FU and/or capecitabine. Detects alterations at 5 major loci on the DPYD gene.	
UGT1A1[§]	Identifies patients at elevated risk for toxicity to irinotecan, sacituzumab govitecan, and/or belinostat. Detects 5 variants from 3 loci on the UGT1A1 gene.	

IMMUNOHISTOCHEMISTRY (IHC) OPTIONS—Available with any xT, xR, or xE test.

PD-L1 Clones	22C3; SP142; 28-8; SP263
MMR	MLH1; MSH2; MSH6; PMS2
HER2[†]	Protein expression *(powered by NeoGenomics)*
FOLR1	Folate Receptor alpha (FRα) expression *(powered by NeoGenomics)*
CLDN18	Claudin-18 expression *(powered by NeoGenomics)*

* *A saliva specimen from the patient is also accepted as the normal match*

§ *xT solid tumor + normal match DNA seq required*

¶ *xR RNA seq required*

† *When HER2 is ordered, it will be reflexed to ERBB2 FISH for all solid tumor types in cases of equivocal results (IHC score of 2+).While FISH reflex will occur for equivocal IHC results in any solid tumor, it is currently only guideline-supported for select tumor types.*[1,2,3]

1 *Northcott J, Bartha G, Harris J, et al. Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget. 2024;15:200-218*

2 *Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867-3872.*

3 *Bartley AN, Washington MK, Ventura CB, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345-1363.*

LEARN MORE

If you have any questions on our comprehensive portfolio please contact your Tempus Representative or email support@tempus.com